logo
  Join        Login             Stock Quote

Depomed (DEPO) Plans To File NDA For Serada To Treat Menopausal Hot Flashes

 April 17, 2012 08:08 PM
 


DepoMed Inc. (NASDAQ:DEPO) said it plans to prepare and file a new drug application with the United States Food and Drug Administration (FDA) for Serada (extended-release gabapentin tablets) to treat menopausal hot flashes.

The company said it has completed a Type B pre-NDA meeting with FDA regarding the results of the three Phase 3 clinical trials of Serada (extended-release gabapentin tablets), Depomed's investigational gastric-retentive, extended-release formulation of gabapentin for menopausal hot flashes.

Based on the recent interactions with FDA, the company believes that data from its Serada clinical trial program warrants submission of an NDA for the FDA's review and consideration.

[Related -Top Insider Purchases: DEPO, DRIV, GUID, NTS, OPK, LMNX]

Chief Executive Jim Schoeneck believes Serada may offer clinical benefit as a non-hormonal treatment option for women suffering from menopausal hot flashes.

In October 2011, Depomed announced the results of the BREEZE 3 clinical trial of Serada and also announced at that time its intention to meet with the FDA to discuss possible pathways to filing a new drug application (NDA) in light of the results of the three Phase 3 trials of Serada completed by Depomed.

Efficacy data from the BREEZE 3 trial were positive and statistically significant for three of the four pre-specified primary endpoints of frequency and severity at four and 12 weeks.

Hot flashes affect 75% of menopausal women or 32 million women annually in the U.S. Hot flashes are characterized by a sudden, temporary onset of body warmth, flushing and sweating. For those menopausal women who suffer, even small fluctuations in body temperature can cause them to experience profuse sweating or severe chills.

[Related -Depomed (DEPO): FDA Panel Votes Against Recommending Menopause Treatment]

Hot flashes are disruptive and impact women's overall quality of life, affecting their mood and their ability to sleep. In fact, insomnia typically worsens with the severity of hot flashes.

According to the North American Menopause Society, hot flashes are the most common menopause-related discomfort. For some women, these symptoms can persist for 10 years or more. The exact cause of hot flashes is not known.

Serada is an investigational extended-release, orally administered formulation of gabapentin for the treatment of menopausal hot flashes using Depomed's proprietary Acuform drug delivery technology.

By combining gabapentin with Acuform technology, Serada is absorbed slowly into the upper gastrointestinal tract over several hours rather than immediately. Serada has not been approved by the FDA for any use at this time.

DEPO closed Tuesday's regular trading up 3.97% at $6.29. The stock has been trading between $4.20 and $9.26 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageHealth Net, Inc. (HNT): Potential to Be Huge Winners Says Bank of America

As of this keystroke, Health Net, Inc. (NYSE: HNT) shares are up around 4% on the day. The managed health read on...

article imageHomeAway, Inc. (AWAY) Q2 Earnings Preview: Top and Bottom Line Bullish Surprise?

HomeAway, Inc. (NASDAQ:AWAY) will report its financial results for the second quarter ended June 30, 2014 read on...

article imageAmazon.com, Inc. (AMZN) Q2 Earnings Preview: Missing on the Top and Bottom Lines, Again?

Amazon.com, Inc. (NASDAQ:AMZN) will release its second quarter financial results after market close on read on...

article imageFord Motor Company (F) Q2 Earnings Preview: Light on the Top Line?

Ford Motor Company (NYSE:F) will release its preliminary second quarter 2014 results at 6:30 a.m. EDT read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.